CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
PRK 124other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00580723
NCT00580723Phase 2Completed
CompareCT.gov

Effects of PRK 124 (0.125%) Lotion in Acne Rosacea

University of California, Irvine·interventional·Posted Dec 27, 2007·Updated Jan 17, 2014

In Brief

A Phase 2 clinical trial evaluating PRK 124 for Acne Rosacea. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Rosacea
CountriesUnited States
CollaboratorsSenetekPLC

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 27, 2007
Enrollment StartApr 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.5 years ago

Interventions

PRK 124other

Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks